Tumor Ablation Market by Technology (Radiofrequency, Microwave, Laser, IRE, HIFU, Cryoablation), Product (Generators, Probes), Mode (Surgical, Laparoscopic, Percutaneous), Cancer (Liver, Lung, Bone), End User (Hospitals, Clinic) & Region - Global Forecast to 2029
Market Growth Outlook Summary
The global tumor ablation market, valued at US$0.7 billion in 2023, is forecasted to grow at a robust CAGR of 10.0%, reaching US$0.8 billion in 2024 and an impressive US$1.4 billion by 2029. Over the years, the ablation technology have evolved significantly, with a focus on improved reliability, real-time monitoring, and faster recovery. These innovations, combined with increasing cancer incidence rates and the need for improved treatment, have driven the growth of the market. As healthcare advances, tumor ablation systems contribute to enhaced and first line treatment for benign tumors. The use of tumor ablation systems for various applications continues to drive innovation and breakthroughs in various domains, benefiting humanity in numerous ways.
Tumor Ablation Market Trends
To know about the assumptions considered for the study, Request for Free Sample Report
e- Estimated; p- Projected
Tumor Ablation Market Dynamics
Driver: Increasing cancer incidence and rising geriatric population
Tumor ablation market is primarily driven by the rising incidence of cancer globally. Tumor ablation is widely used for the treatment of lung cancer, liver cancer, prostate cancer, bone cancer, and kidney cancer among others. According to WHO, cancer was the major cause of death globally in 2020 -accounted for around 10 mn deaths. Emerging economies in Asia, Africa, and Oceania reported 55% of the 18.1 million cancer cases diagnosed. With the continuous rise in the global cancer patient population, there is expected to be a significant increase in demand for tumor ablation procedures during the forecast period.
Restraint: Increasing cancer incidence and rising geriatric population
High cost of tumor ablation systems is one of the restrains in tumor ablation market. Premium product pricing hinders the adoption in emerging countries. Small healthcare facilities rely on third-party payers to reimburse the costs incurred in diagnostic, screening, and therapeutic procedures. The high cost of the equipment makes it difficult for most hospitals in emerging economies to afford this technology. Hence, smaller end users are hesitant to invest in this equipment.
Opportunity: Rising healthcare expenditure across emerging economies
Growing healthcare expenditure in emerging nations such as China, India, Brazil, and Mexico are expected to offer lucrative opportunities for tumor ablation market. For instance, according to GLOBOCAN 2020 data, over 50% of the global cancer population resides in emerging economies. Increasing government initiatives towards providing advanced healthcare services and improving reimbursement coverage support the adoption of tumor ablation devices. rapid increase in the per-capita healthcare expenditure and the rising public demand for affordable healthcare in emerging economies to further expected to drive the demand for ablation systems in developing countries.
Challenge: Rising adoption of refurbished tumor ablation systems
Small scale end users specifically in developing countries often opt for refurbished alternatives as a cost-effective solution. Refurbished systems are sold at a fraction of the cost of new equipment Refurbished systems are sold at a fraction of the cost of new equipment. Due to similar functioning and affordable cost the adoption of refurbished systems is experiencing a surge in the adoption. This poses a challenge for smaller manufacturers who are struggling to keep up and is expected to impact the market growth.
Tumor Ablation Industry Ecosystem.
By Technology, the radiofrequency ablation segment accounted for the largest share of the tumor ablation industry.
Based on technology, the tumor ablation market is segmented into radiofrequency ablation, microwave ablation, high intensity focused ultrasound (HIFU), cryoablation, and other technologies. In 2023, the radiofrequency ablation segment accounted for the largest market share. Rising awareness of proactive health and expansion of market players fuel the growth of tumor ablation market.
By Product Type, the generators segment of the tumor ablation industry to register significant growth in the near future.
Based on product type, the tumor ablation market is segmented into generators probes and electrodes. The generators segment accounted for the largest market share in 2023. The demand for minimally invasive procedures is increasing due to the emphasis on improving quality of life. Additionally, favorable regulatory scenarios and a surge in oncological surgeries contribute to the rising adoption of tumor ablation systems.
The laparoscopic ablation segment for mode of treatment segment is expected to register a higher CAGR of the tumor ablation industry forecast period.
Based on mode of treatment, the tumor ablation market is segmented into laparoscopic ablation, surgical ablation, and percutaneous ablation. Increasing collaboration between industry players and healthcare providers and integration of ablation systems with other treatment modalities contribute to the growth of this segment. Laparoscopic ablation has improved benefits as compared to other modes of treamtnets. Factors such as reduced pain, greater visibility due to laparoscopic cameras, quick recovery, and shorter stays at the hospitals contribute to the exponential growth of this segment.
The liver cancer segment for application segment held the largest share of the tumor ablation industry.
Based on application, the tumor ablation market is segmented into liver cancer, kidney cancer, lung cancer, bone cancer, and other applications. Liver cancer segment held largest share of the market in 2023 and is also expected to register a significant growth rate from 2024 to 2029. Increasing adoption of image-guided therapies and increasing funding opportunities for cancer research are driving the adoption.
By end user, the hospitals and clinic centers segment of the tumor ablation industry held the largest share.
The tumor ablation market is segmented by end users into hospitals and clinics, cancer care centers, and other end users. However, the cancer care centers segment is expected to grow at the highest CAGR during the forecast period. The rise in number of chronic diseases, including cancer, increasing cancer diagnostic procedures in the hospitals globally, and the potential of benefits of ablation observed in patients with early stage cancer have contributed to the growth of this segment.
By region, North America is expected to be the largest market of the tumor ablation industry by 2029.
The US and Canada accounted for a significant market share in 2023. North America's faster growth in the tumor ablation market can be attributed to its technological leadership, robust healthcare infrastructure, favorable insurance coverage, growing funding and grants for developing advanced medical equipment, favorable regulatory scenario, strategic research collaboration, and a supportive market environment fostering innovation.
To know about the assumptions considered for the study, download the pdf brochure
As of 2023, prominent players in the market are Johnson & Johnson MedTech (US), Medtronic Plc (Ireland), Stryker Corporation (US), Varian Medical Systems, Inc. (US), Olympus (Japan), AngioDynamics, Inc. (US), Boston Scientific Corporation (US), IceCure Medical Ltd. (Israel), Bioventus Inc. (US).
Tumor Ablation Market Report Scope
Report Metric |
Details |
Market Revenue in 2024 |
$0.8 billion |
Projected Revenue by 2029 |
$1.4 billion |
Revenue Rate |
Poised to Grow at a CAGR of 10.0% |
Market Driver |
Increasing cancer incidence and rising geriatric population |
Market Opportunity |
Rising healthcare expenditure across emerging economies |
This report has segmented the global tumor ablation market to forecast revenue and analyze trends in each of the following submarkets:
By Technology
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- High-intensity Focused Ultrasound
- Other Technologies
By Product Type
- Generators
- Probes/electrodes
By Mode Of Treatment
- Surgical Ablation
- Percutaneous Ablation
- Laparoscopic Ablation
By Application
- Liver Cancer
- Lung Cancer
- Kidney Cancer
- Bone Cancer
- Other Applications
By End User
- Hospitals & clinics
- Cancer care centers
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia Pacific
-
Latin America
- Brazil
- Mexico
- Rest of Latin America
Recent Developments of the Tumor Ablation Market
- In May 2023, Varian launched the Isolis cryoprobe for CryoCare systems. These are disposable probes with improved efficiency and precision for cryoablation. It helps with tumor ablation. They also support accuracy and help to reduce procedure time.
- In April 2023, AngioDynamics extended its partnership with Cardiva. The collaboration aims to introduce AngioDynamics’ oncology products across Europe.
Frequently Asked Questions (FAQ):
What is the projected growth of the global tumor ablation market between 2024 and 2029?
The global tumor ablation market is projected to grow from USD 0.8 billion in 2024 to USD 1.4 billion by 2029, demonstrating a robust CAGR of 10.0%.
What are the key drivers of the tumor ablation market?
The tumor ablation market is primarily driven by the rising incidence of cancer and the growing geriatric population, as well as the increasing demand for minimally invasive procedures to treat liver, lung, prostate, and kidney cancers.
What are the main challenges faced by the tumor ablation market?
The high cost of tumor ablation systems and the adoption of refurbished systems in emerging markets are key challenges. Additionally, smaller healthcare facilities often face difficulties in acquiring and maintaining high-end ablation equipment.
Which regions are expected to witness significant growth in the tumor ablation market?
Emerging economies such as China, India, and Brazil are expected to witness significant growth in the tumor ablation market due to rising healthcare expenditure, government initiatives, and increasing cancer cases.
Which cancer types are most commonly treated using tumor ablation?
Tumor ablation is commonly used to treat liver cancer, lung cancer, kidney cancer, and bone cancer. Among these, liver cancer holds the largest market share, driven by the increasing adoption of image-guided therapies.
What are the recent technological advancements in tumor ablation?
Recent technological advancements include the development of high-intensity focused ultrasound (HIFU), microwave ablation, and cryoablation technologies, which provide better precision and reduced damage to healthy tissues during tumor ablation procedures.
What role do hospitals and clinics play in the tumor ablation market?
Hospitals and clinics are the primary end-users of tumor ablation devices, accounting for the largest market share. These facilities are pivotal in performing minimally invasive ablation procedures for cancer patients, with increasing demand for oncological surgeries.
How is the growing geriatric population affecting the tumor ablation market?
The growing geriatric population is contributing to a higher incidence of cancer, leading to increased demand for tumor ablation procedures. Older adults are more prone to cancers like liver, lung, and kidney cancer, driving market growth.
What are the most widely used tumor ablation technologies?
Radiofrequency ablation is the most widely used technology in the tumor ablation market, followed by microwave ablation and cryoablation. These technologies are preferred due to their high success rates in treating various cancers with minimal invasiveness.
What are the opportunities for growth in the tumor ablation market?
Key growth opportunities in the tumor ablation market include rising healthcare expenditure in emerging economies, expanding government initiatives, and increasing public demand for advanced cancer treatment options, especially in regions like China, India, and Brazil.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
- 5.1 INTRODUCTION
-
5.2 MARKET DYNAMICSDRIVERS- Increasing cancer incidence and rising geriatric population- Rising focus on minimally invasive procedures- Technological advancements in field of tumor ablation- Rising number of awareness campaigns and early detectionRESTRAINTS- High cost of tumor ablation systems- Unfavorable regulatory scenarioOPPORTUNITIES- Rising healthcare expenditure across emerging economies- Increasing number of hospitalsCHALLENGES- Rising adoption of refurbished tumor ablation systems- Hospital budget cuts
-
5.3 REGULATORY ANALYSISKEY REGULATORY BODIES AND GOVERNMENT AGENCIESKEY REGULATORY GUIDELINES- US- Canada- Europe- Asia Pacific- Latin America
- 5.4 REIMBURSEMENT SCENARIO
-
5.5 VALUE CHAIN ANALYSISRESEARCH & DEVELOPMENTMANUFACTURING & ASSEMBLYDISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
-
5.6 SUPPLY CHAIN ANALYSISPROMINENT COMPANIESSMALL AND MEDIUM-SIZED ENTERPRISESEND USERS
- 5.7 ECOSYSTEM ANALYSIS
- 5.8 INVESTMENT & FUNDING SCENARIO
- 5.9 PRICING ANALYSIS
- 5.10 TRADE ANALYSIS
- 5.11 PATENT ANALYSIS
-
5.12 PORTER’S FIVE FORCE ANALYSISTHREAT OF NEW ENTRANTSTHREAT OF SUBSTITUTESBARGAINING POWER OF SUPPLIERSBARGAINING POWER OF BUYERSINTENSITY OF COMPETITIVE RIVALRY
- 5.13 KEY CONFERENCES & EVENTS IN 2024–2025
- 5.14 CASE STUDY ANALYSIS
-
5.15 TECHNOLOGY ANALYSISKEY TECHNOLOGIES- Radiofrequency ablation and microwave ablation- CryoablationCOMPLEMENTARY TECHNOLOGIES- Laparoscopy- Diagnostic imagingADJACENT TECHNOLOGIES- Electrosurgery
- 5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
-
5.17 KEY STAKEHOLDERS & BUYING CRITERIAKEY STAKEHOLDERS IN BUYING PROCESSBUYING CRITERIA
- 5.18 UNMET NEEDS & KEY PAIN POINTS
- 6.1 INTRODUCTION
-
6.2 RADIOFREQUENCY ABLATIONLOW COST OF RADIOFREQUENCY ABLATION TO CONTRIBUTE TO MARKET GROWTH
-
6.3 MICROWAVE ABLATIONADVANTAGES OF MICROWAVE ABLATION TO BOOST MARKET GROWTH
-
6.4 CRYOABLATIONHIGH SAFETY AND EFFICACY OF CRYOABLATION TO BOOST MARKET
-
6.5 HIGH-INTENSITY-FOCUSED ULTRASOUND (HIFU)TECHNOLOGICAL ADVANCEMENTS IN ULTRASOUND ABLATION TO FAVOR MARKET GROWTH
- 6.6 OTHER TECHNOLOGIES
- 7.1 INTRODUCTION
-
7.2 GENERATORSRISING ADOPTION OF TUMOR ABLATION SYSTEMS TO PROPEL MARKET GROWTH
-
7.3 PROBES/ELECTRODESRADIOFREQUENCY ABLATION PROBES- Rising adoption of radiofrequency ablation systems for multiple applications to propel market growthMICROWAVE ABLATION PROBES- Increasing cancer prevalence and precise ablation to boost adoptionOTHER PROBES/ELECTRODES
- 8.1 INTRODUCTION
-
8.2 SURGICAL ABLATIONRISING UTILIZATION OF SURGICAL ABLATION IN END-USER FACILITIES TO PROPEL MARKET
-
8.3 LAPAROSCOPIC ABLATIONIMPROVED SUCCESS RATE AND REAL-TIME VISUALIZATION TO BOOST DEMAND
-
8.4 PERCUTANEOUS ABLATIONSHORTER RECOVERY TIME AND COST-EFFECTIVENESS OF PROCEDURE TO DRIVE SEGMENT
- 9.1 INTRODUCTION
-
9.2 LIVER CANCERPROMISING OUTCOMES OF ABLATION IN TREATING HCC TO DRIVE MARKET
-
9.3 LUNG CANCERRISING INCIDENCE OF LUNG CANCER TO FUEL MARKET
-
9.4 KIDNEY CANCERRISING PREVALENCE OF KIDNEY CANCER AND MINIMAL DAMAGE OF HEALTHY TISSUE TO DRIVE ADOPTION
-
9.5 BONE CANCERRISING USE OF ABLATION TECHNIQUES TO TREAT OSTEOID OSTEOMA TO BOOST GROWTH
- 9.6 OTHER APPLICATIONS
- 10.1 INTRODUCTION
-
10.2 HOSPITALS & CLINICSINCREASING ADOPTION OF ADVANCED TUMOR ABLATION SYSTEMS TO PROPEL MARKET
-
10.3 CANCER CARE CENTERSGROWING ESTABLISHMENT OF CANCER CARE CENTERS TO FUEL MARKET
- 10.4 OTHER END USERS
- 11.1 INTRODUCTION
-
11.2 NORTH AMERICANORTH AMERICA: RECESSION IMPACTUS- Rising prevalence of cancer to propel market growthCANADA- Growing burden of cancer to support market growth
-
11.3 EUROPEEUROPE: RECESSION IMPACTGERMANY- Highly developed healthcare infrastructure and rising disease incidence to ensure strong growth prospectsFRANCE- Growing geriatric population to support market growth in FranceUK- Growing target patient population to support market growth in UKITALY- Rising awareness to support market growthSPAIN- Increasing government funding for research to support market growthREST OF EUROPE
-
11.4 ASIA PACIFICASIA PACIFIC: RECESSION IMPACTJAPAN- Presence of universal healthcare reimbursement scenario to drive market growthCHINA- Increasing patient pool and government initiatives for healthcare development to fuel market growthINDIA- Ongoing modernization and infrastructure development in India to support market growthAUSTRALIA- Rising research investments and awareness campaigns to support market growthSOUTH KOREA- Rising R&D and promising clinical trials to positively impact market growthREST OF ASIA PACIFIC
-
11.5 LATIN AMERICALATIN AMERICA: RECESSION IMPACTBRAZIL- Modernization of healthcare facilities in Brazil to boost marketMEXICO- Availability of advanced care and increasing awareness programs to fuel market growth in MexicoREST OF LATIN AMERICA
-
11.6 MIDDLE EAST & AFRICAIMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTHMIDDLE EAST & AFRICA: RECESSION IMPACT
- 12.1 OVERVIEW
-
12.2 KEY PLAYER STRATEGIES/RIGHT TO WINOVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN TUMOR ABLATION MARKET
- 12.3 REVENUE ANALYSIS
- 12.4 MARKET SHARE ANALYSIS
-
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023STARSEMERGING LEADERSPERVASIVE PLAYERSPARTICIPANTSCOMPANY FOOTPRINT: KEY PLAYERS, 2023- Company footprint- Technology footprint- Region footprint
-
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023PROGRESSIVE COMPANIESRESPONSIVE COMPANIESDYNAMIC COMPANIESSTARTING BLOCKSCOMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
-
12.7 COMPANY VALUATION & FINANCIAL METRICSFINANCIAL METRICSCOMPANY VALUATION
- 12.8 BRAND/PRODUCT COMPARISON
-
12.9 COMPETITIVE SCENARIOPRODUCT LAUNCHES/APPROVALSDEALSEXPANSIONS
-
13.1 KEY PLAYERSMEDTRONIC PLC- Business overview- Products offered- Recent developments- MnM viewJOHNSON & JOHNSON MEDTECH (ETHICON)- Business overview- Products offered- MnM viewSTRYKER CORPORATION- Business overview- Products offered- Recent developments- MnM viewVARIAN MEDICAL SYSTEMS, INC.- Business overview- Products offered- Recent developmentsANGIODYNAMICS, INC.- Business overview- Products offered- Recent developmentsBOSTON SCIENTIFIC CORPORATION- Business overview- Products offeredEDAP TMS S.A.- Business overview- Products offeredMERMAID MEDICAL- Business overview- Products offeredCANYON MEDICAL INC.- Business overview- Products offeredOLYMPUS CORPORATION- Business overview- Products offered- Recent developmentsCHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.- Business overview- Products offeredMERIT MEDICAL SYSTEMS, INC.- Business overview- Products offeredBIOVENTUS INC.- Business overview- Products offered- Recent developmentsICECURE MEDICAL LTD.- Business overview- Products offered- Recent developmentsCONMED CORPORATION- Business overview- Products offered
-
13.2 OTHER PLAYERSMONTERIS MEDICALMIANYANG SONIC ELECTRONICRF MEDICALMINIMAX MEDICAL HOLDING GROUPSONABLATEECO MEDICAL TECHNOLOGY (NANJING) CO., LTD.STARMED CO., LTD.SURGNOVACREO MEDICALMEDSPHERE SHANGHAI
- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS
- TABLE 1 NORTH AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
- TABLE 2 EUROPE: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
- TABLE 3 ASIA PACIFIC: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
- TABLE 4 LATIN AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
- TABLE 5 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
- TABLE 6 US FDA: MEDICAL DEVICE CLASSIFICATION
- TABLE 7 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
- TABLE 8 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
- TABLE 9 JAPAN: PMDA CLASSIFICATION OF ABLATION DEVICES
- TABLE 10 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
- TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES
- TABLE 12 INDIA: CDSCO CLASSIFICATION OF ABLATION DEVICES
- TABLE 13 MEDICAL REIMBURSEMENT CPT CODES FOR MICROWAVE AND RADIOFREQUENCY ABLATION PROCEDURES IN US (EFFECTIVE JANUARY 1, 2022)
- TABLE 14 TUMOR ABLATION MARKET: ROLE IN ECOSYSTEM
- TABLE 15 AVERAGE SELLING PRICE OF TUMOR ABLATION SYSTEMS, BY REGION, 2021–2023
- TABLE 16 IMPORT DATA FOR TUMOR ABLATION SYSTEMS (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND)
- TABLE 17 EXPORT DATA FOR TUMOR ABLATION SYSTEMS (HS CODE 9018), BY COUNTRY, 2018–2022 (USD THOUSAND)
- TABLE 18 PORTER’S FIVE FORCES ANALYSIS: TUMOR ABLATION MARKET
- TABLE 19 LIST OF MAJOR CONFERENCES & EVENTS IN TUMOR ABLATION MARKET, 2024–2025
- TABLE 20 CASE STUDY 1: RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY
- TABLE 21 CASE STUDY 2: ABLATION OF LOCALIZED RENAL TUMOR
- TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
- TABLE 23 KEY BUYING CRITERIA FOR TUMOR ABLATION SYSTEMS
- TABLE 24 TUMOR ABLATION MARKET: CURRENT UNMET NEEDS
- TABLE 25 TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 26 RADIOFREQUENCY ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 27 MICROWAVE ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 28 CRYOABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 29 HIGH-INTENSITY-FOCUSED ULTRASOUND MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 30 OTHER TUMOR ABLATION TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 31 TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
- TABLE 32 TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (UNITS)
- TABLE 33 TUMOR ABLATION GENERATORS MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 34 RADIOFREQUENCY ABLATION PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 35 MICROWAVE ABLATION PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 36 OTHER TUMOR ABLATION PROBES/ELECTRODES MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 37 TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
- TABLE 38 TUMOR ABLATION MARKET FOR SURGICAL ABLATION, BY REGION, 2022–2029 (USD MILLION)
- TABLE 39 TUMOR ABLATION MARKET FOR LAPAROSCOPIC ABLATION, BY REGION, 2022–2029 (USD MILLION)
- TABLE 40 TUMOR ABLATION MARKET FOR PERCUTANEOUS ABLATION, BY REGION, 2022–2029 (USD MILLION)
- TABLE 41 TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 42 TUMOR ABLATION MARKET FOR LIVER CANCER, BY REGION, 2022–2029 (USD MILLION)
- TABLE 43 TUMOR ABLATION MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION)
- TABLE 44 TUMOR ABLATION MARKET FOR KIDNEY CANCER, BY REGION, 2022–2029 (USD MILLION)
- TABLE 45 TUMOR ABLATION MARKET FOR BONE CANCER, BY REGION, 2022–2029 (USD MILLION)
- TABLE 46 TUMOR ABLATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
- TABLE 47 TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 48 TUMOR ABLATION MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)
- TABLE 49 TUMOR ABLATION MARKET FOR CANCER CARE CENTERS, BY REGION, 2022–2029 (USD MILLION)
- TABLE 50 TUMOR ABLATION MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
- TABLE 51 TUMOR ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
- TABLE 52 NORTH AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 53 NORTH AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 54 NORTH AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
- TABLE 55 NORTH AMERICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
- TABLE 56 NORTH AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 57 NORTH AMERICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 58 US: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 59 CANADA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 60 EUROPE: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 61 EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 62 EUROPE: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
- TABLE 63 EUROPE: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
- TABLE 64 EUROPE: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 65 EUROPE: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 66 GERMANY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 67 FRANCE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 68 UK: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 69 ITALY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 70 SPAIN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 71 REST OF EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 72 ASIA PACIFIC: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 73 ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 74 ASIA PACIFIC: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
- TABLE 75 ASIA PACIFIC: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
- TABLE 76 ASIA PACIFIC: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 77 ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 78 JAPAN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 79 CHINA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 80 INDIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 81 AUSTRALIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 82 SOUTH KOREA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 83 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 84 LATIN AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
- TABLE 85 LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 86 LATIN AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
- TABLE 87 LATIN AMERICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
- TABLE 88 LATIN AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 89 LATIN AMERICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 90 BRAZIL: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 91 MEXICO: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 92 REST OF LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 93 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
- TABLE 94 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
- TABLE 95 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
- TABLE 96 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
- TABLE 97 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
- TABLE 98 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
- TABLE 99 TUMOR ABLATION TECHNOLOGY MARKET: DEGREE OF COMPETITION
- TABLE 100 TUMOR ABLATION MARKET: TECHNOLOGY FOOTPRINT
- TABLE 101 TUMOR ABLATION MARKET: REGION FOOTPRINT
- TABLE 102 TUMOR ABLATION MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
- TABLE 103 TUMOR ABLATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
- TABLE 104 TUMOR ABLATION MARKET: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2024
- TABLE 105 TUMOR ABLATION MARKET: DEALS, JANUARY 2021–MARCH 2024
- TABLE 106 TUMOR ABLATION MARKET: EXPANSIONS, JANUARY 2021–MARCH 2024
- TABLE 107 MEDTRONIC PLC: COMPANY OVERVIEW
- TABLE 108 MEDTRONIC PLC: PRODUCTS OFFERED
- TABLE 109 MEDTRONIC PLC: PRODUCT APPROVALS
- TABLE 110 JOHNSON & JOHNSON MEDTECH: COMPANY OVERVIEW
- TABLE 111 JOHNSON & JOHNSON MEDTECH: PRODUCTS OFFERED
- TABLE 112 STRYKER CORPORATION: COMPANY OVERVIEW
- TABLE 113 STRYKER CORPORATION: PRODUCTS OFFERED
- TABLE 114 STRYKER CORPORATION: PRODUCT APPROVALS
- TABLE 115 STRYKER CORPORATION: EXPANSIONS
- TABLE 116 VARIAN MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW
- TABLE 117 VARIAN MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED
- TABLE 118 VARIAN MEDICAL SYSTEMS, INC.: PRODUCT LAUNCHES
- TABLE 119 VARIAN MEDICAL SYSTEMS, INC.: DEALS
- TABLE 120 ANGIODYNAMICS, INC.: COMPANY OVERVIEW
- TABLE 121 ANGIODYNAMICS, INC.: PRODUCTS OFFERED
- TABLE 122 ANGIODYNAMICS, INC.: DEALS
- TABLE 123 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
- TABLE 124 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
- TABLE 125 EDAP TMS S.A.: COMPANY OVERVIEW
- TABLE 126 EDAP TMS S.A.: PRODUCTS OFFERED
- TABLE 127 MERMAID MEDICAL: COMPANY OVERVIEW
- TABLE 128 MERMAID MEDICAL: PRODUCTS OFFERED
- TABLE 129 CANYON MEDICAL INC.: COMPANY OVERVIEW
- TABLE 130 CANYON MEDICAL INC.: PRODUCTS OFFERED
- TABLE 131 OLYMPUS CORPORATION: COMPANY OVERVIEW
- TABLE 132 OLYMPUS CORPORATION: PRODUCTS OFFERED
- TABLE 133 OLYMPUS CORPORATION: PRODUCT LAUNCHES
- TABLE 134 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
- TABLE 135 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.: PRODUCTS OFFERED
- TABLE 136 MERIT MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW
- TABLE 137 MERIT MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED
- TABLE 138 BIOVENTUS INC.: COMPANY OVERVIEW
- TABLE 139 BIOVENTUS INC.: PRODUCTS OFFERED
- TABLE 140 BIOVENTUS INC.: DEALS
- TABLE 141 ICECURE MEDICAL LTD.: COMPANY OVERVIEW
- TABLE 142 ICECURE MEDICAL LTD.: PRODUCTS OFFERED
- TABLE 143 ICECURE MEDICAL LTD.: PRODUCT APPROVALS
- TABLE 144 ICECURE MEDICAL LTD.: DEALS
- TABLE 145 CONMED CORPORATION: COMPANY OVERVIEW
- TABLE 146 CONMED CORPORATION: PRODUCTS OFFERED
- FIGURE 1 RESEARCH DESIGN
- FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
- FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
- FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
- FIGURE 5 TUMOR ABLATION MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)
- FIGURE 6 TUMOR ABLATION MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
- FIGURE 7 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
- FIGURE 8 DATA TRIANGULATION METHODOLOGY
- FIGURE 9 TUMOR ABLATION MARKET, TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
- FIGURE 10 TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024 VS. 2029 (USD MILLION)
- FIGURE 11 TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2024 VS. 2029 (USD MILLION)
- FIGURE 12 TUMOR ABLATION MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
- FIGURE 13 TUMOR ABLATION MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
- FIGURE 14 TUMOR ABLATION MARKET: GEOGRAPHIC SNAPSHOT
- FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
- FIGURE 16 MICROWAVE ABLATION SEGMENT TO REGISTER SIGNIFICANT GROWTH IN NORTH AMERICA DURING FORECAST PERIOD
- FIGURE 17 LIVER CANCER SEGMENT TO DOMINATE MARKET IN EUROPE DURING FORECAST PERIOD
- FIGURE 18 HOSPITALS & CLINICS SEGMENT TO CONTINUE TO HOLD LARGEST SHARE IN ASIA PACIFIC MARKET
- FIGURE 19 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
- FIGURE 20 TUMOR ABLATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
- FIGURE 21 PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES
- FIGURE 22 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES
- FIGURE 23 EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES
- FIGURE 24 TUMOR ABLATION MARKET: VALUE CHAIN ANALYSIS
- FIGURE 25 TUMOR ABLATION MARKET: SUPPLY CHAIN ANALYSIS
- FIGURE 26 TUMOR ABLATION MARKET: ECOSYSTEM ANALYSIS
- FIGURE 27 NUMBER OF INVESTOR DEALS IN TUMOR ABLATION MARKET, BY KEY PLAYER, 2018–2022
- FIGURE 28 VALUE OF INVESTOR DEALS IN TUMOR ABLATION MARKET, BY KEY PLAYER, 2018–2022 (USD MILLION)
- FIGURE 29 AVERAGE SELLING PRICE TREND OF TUMOR ABLATION SYSTEMS, BY TECHNOLOGY
- FIGURE 30 AVERAGE SELLING PRICE TREND OF TUMOR ABLATION SYSTEMS, BY REGION
- FIGURE 31 PATENT DETAILS FOR TUMOR ABLATION MARKET (JANUARY 2013– DECEMBER 2023)
- FIGURE 32 REVENUE SHIFT IN TUMOR ABLATION MARKET
- FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE CATEGORIES
- FIGURE 34 KEY BUYING CRITERIA FOR PROCESS TUMOR ABLATION SYSTEMS
- FIGURE 35 NORTH AMERICA: TUMOR ABLATION MARKET SNAPSHOT
- FIGURE 36 ASIA PACIFIC: TUMOR ABLATION MARKET SNAPSHOT
- FIGURE 37 REVENUE ANALYSIS OF TOP THREE PLAYERS IN TUMOR ABLATION MARKET (2021–2023)
- FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
- FIGURE 39 TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
- FIGURE 40 TUMOR ABLATION MARKET: COMPANY FOOTPRINT
- FIGURE 41 TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
- FIGURE 42 EV/EBITDA OF KEY VENDORS
- FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
- FIGURE 44 BRAND/PRODUCT COMPARATIVE ANALYSIS
- FIGURE 45 MEDTRONIC PLC: COMPANY SNAPSHOT (2023)
- FIGURE 46 JOHNSON & JOHNSON MEDTECH: COMPANY SNAPSHOT (2022)
- FIGURE 47 STRYKER CORPORATION: COMPANY SNAPSHOT (2023)
- FIGURE 48 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2023)
- FIGURE 49 ANGIODYNAMICS, INC.: COMPANY SNAPSHOT (2023)
- FIGURE 50 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023)
- FIGURE 51 EDAP TMS S.A.: COMPANY SNAPSHOT (2023)
- FIGURE 52 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2023)
- FIGURE 53 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022)
- FIGURE 54 BIOVENTUS INC.: COMPANY SNAPSHOT (2023)
- FIGURE 55 ICECURE MEDICAL LTD.: COMPANY SNAPSHOT (2023)
- FIGURE 56 CONMED CORPORATION: COMPANY SNAPSHOT (2023)
The study involved four major activities in estimating the current size of the tumor ablation market. Exhaustive secondary research was done to collect information on the market, peer, and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial tumor ablation market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the tumor ablation market. The primary sources from the demand side include hospitals, clinics, retailers, and other end users. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.
A breakdown of the primary respondents is provided below:
*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
The tiers of the companies are defined based on their total revenue. As of 2023: Tier 1 => USD 1 billion, Tier 2 = USD 200-500 million to USD 1 billion, and Tier 3 =< USD 200 million
To know about the assumptions considered for the study, download the pdf brochure
Market Estimation Methodology
In this report, the tumor ablation market’s size was determined using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the market business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.
Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:
- Generating a list of major global players operating in the tumor ablation market.
- Mapping annual revenues generated by major global players from the product segment (or nearest reported business unit/product category)
- Revenue mapping of major players to cover a major share of the global market share, as of 2022
- Extrapolating the global value of the tumor ablation market industry
Bottom-up approach
In this report, the size of the global tumor ablation market was determined using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the tumor ablation business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and marketing executives.
Approach 1: Company revenue estimation approach
To calculate the global market value, segmental revenues were calculated based on the revenue mapping of major solution/product providers. This process involved the following steps:
- Generating a list of major global players operating in the tumor ablation market
- Mapping the annual revenues generated by major global players from the tumor ablation segment (or the nearest reported business unit/product category)
- Mapping the revenues of major players to cover at least 50-55% of the global market share as of 2023
- Extrapolating the global value of the tumor ablation industry
Market Size Estimation For Tumor Ablation: Approach 1 (Company Revenue Estimation)I
To know about the assumptions considered for the study, Request for Free Sample Report
Approach 2: Customer-based market estimation
During preliminary secondary research, the total sales revenue of tumor ablation was estimated and validated at the regional and country level, triangulated, and validated to estimate the global market value. This process involved the following steps:
- Generating a list of major customer facilities across each region and country
- Identifying the average number of tumor ablation product supplies used by major customer facilities across each product type at the regional/country level, annually
- Identifying the percentage contribution of major customer facilities to the overall tumor ablation expenditure and usage at the regional/country level, annually
- Extrapolating the annual usage patterns for various products across major customer facilities to estimate the size of each product segment at the regional/country level, annually
- Identifying the percentage contributions of individual market segments and subsegments to the overall tumor ablation market at the regional/country level
Tumor Ablation Market Size Estimation: Bottom-Up Approach
Source: MarketsandMarkets Analysis
Data Triangulation
After arriving at the overall market size from the market size estimation process explained above, the global tumor ablation market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the tumor ablation market was validated using top-down and bottom-up approaches.
Market Definition
Tumor ablation is a minimally invasive surgical procedure used to remove or destroy cancerous tissue from the affected area as part of cancer management and treatment. The targeted tissue is subjected to ablating energy through surgical, laparoscopic, or percutaneous methods. This technique is commonly used for treating liver, bone, lung, kidney, prostate, and other types of cancer.
Key Stakeholders
- Tumor ablation product manufacturers
- Original equipment manufacturers (OEMs)
- Suppliers, distributors, and channel partners
- Healthcare service providers
- Hospitals and academic medical centers
- Interventional radiologists
- Research laboratories
- Health insurance providers
- Government bodies/organizations
- Regulatory bodies
- Medical research institutes
- Business research and consulting service providers
- Venture capitalists and other public-private funding agencies
- Market research and consulting firms
Objectives of the Study
- To define, describe, and forecast the tumor ablation market based on technology, product type, mode of treatment, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the revenue of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, Middle East and Africa
- To profile the key players and comprehensively analyze their market ranking and core competencies
- To benchmark players within the market using a proprietary competitive leadership mapping framework, which analyzes market players on various parameters within the broad categories of market share and product footprint
Available Customizations
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the present global tumor ablation market report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of the top five companies
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Geographic Analysis
- Further breakdown of the Rest of Europe tumor ablation market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among others
- Further breakdown of the Rest of Asia Pacific tumor ablation market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries
- Further breakdown of the Rest of Latin America (RoLATAM), which comprises Argentina, Chile, Peru, Colombia, and Cuba
Growth opportunities and latent adjacency in Tumor Ablation Market